Category: Intellectual property
-
Purdue Licenses Food Pathogen Fingerprint Technology
26 January 2016. A lab equipment company is licensing a laser-based technology developed at Purdue University that quickly identifies foodborne pathogens. Financial aspects of the agreement between Purdue, in West Lafayette, Indiana and Andreas Hettich GmbH in Tuttlingen, Germany were not disclosed. Hettich is acquiring the rights to Bacteria Rapid Detection using Optical Scattering Technology,…
-
Company Founded to Advance Concussion Treatment
21 January 2016. A San Diego surgeon who conducts research on traumatic brain injury started a new company to take his discovery of a drug for treating concussions to market. The company, Oxeia Biopharmaceuticals founded by Vishal Bansal, began operations today, and revealed its corporate and scientific boards. Bansal studied the connection between metabolic and…
-
Zoetis Inks Deal for Antibiotic Alternative in Animals
19 January 2016. The veterinary medicines company Zoetis is gaining exclusive rights to evaluate and possibly license an alternative to antibiotics in farm animals. While some financial details of the agreement with Anatara Lifesciences in Brisbane, Australia were disclosed, dollar amounts were not revealed. Antibiotics are used to treat disease in livestock and reduce food-borne…
-
Boehringer, Arena to Discover Neurological Drugs
13 January 2016. Pharmaceutical companies Boehringer Ingelheim and Arena Pharmaceuticals Inc. are collaborating on discovery of new therapies for schizophrenia and other neurological disorders. The partnership could bring Arena, in San Diego, as much as $262 million. Arena Pharmaceuticals is a biopharmaceutical company developing therapies for disorders related to G protein-coupled receptors, or GPCRs, proteins…
-
Juno Acquires Biotech, Licenses Cell Sequencing Tech
11 January 2016. Juno Therapeutics is gaining single-cell sequencing technology for cancer immunotherapies through the buy-out of biotechnology company AbVitro Inc., and licensing part of that technology to pharmaceutical company Celgene Corp. The AbVitro acquisition is valued at about $125 million, while financial details of the licensing deal with Celgene are not disclosed. Juno Therapeutics,…
-
Grünenthal Group to Commercialize Duchenne Therapy
8 January 2015. Grünenthal Group, a German pharmaceutical company, is licensing a treatment candidate for Duchenne muscular dystrophy developed by Akashi Therapeutics, a biopharmaceutical company created by organizations advocating for research on the disease. While full financial details of the agreement were not disclosed, Grünenthal says it’s committing more than $100 million to the venture.…
-
Patent Awarded for Liquid Biopsy Technology
4 January 2016. A new U.S. patent was awarded for a technology that detects a broad range of cancers in blood, rather than taking tissue samples for analysis, usually requiring surgery. Jacob Micallef, chief scientist at VolitionRx, a developer of cancer diagnostics in Namur, Belgium, received patent number 9,222,937 on 29 December 2015 from the…
-
Start-Up Licenses Founder’s Research for Resistant Bacteria
22 December 2015. A biotechnology company spun-off from University of California in San Diego is licensing technology from the university to develop treatments for bacterial infections now becoming resistant to conventional antibiotics. Financial terms of the licensing agreement between UC-San Diego and Forge Therapeutics were not disclosed. Forge Therapeutics, also in San Diego, is licensing…
-
Biotech, Bayer Partner on Gene-Editing Treatments
21 December 2015. CRISPR Therapeutics and the drug company Bayer AG are forming a joint venture to develop gene-editing therapies for three types of genetic diseases, and later for other human and agricultural applications. The deal calls for Bayer AG, in Leverkusen, Germany, to invest at least $300 million in the joint venture and take…
-
Lilly Licensing Biotech’s Drug Injection Technology
21 December 2015. Eli Lilly and Company is licensing a technology from Halozyme Therapeutics that makes it possible to inject biologic drugs under the skin rather than with intravenous infusions. The deal could bring Halozyme Therapeutics, a biotechnology company in San Diego, as much as $825 million. Halozyme develops synthetic enzymes, with a technology platform, called Enhanze…